Royalty Report: Drugs, Pharmaceuticals, Delivery – Collection: 27099

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Delivery
  • Therapeutic
  • Disease
  • Hormones
  • Tobacco

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4414

License Grant
The Swiss Company has granted Licensee an exclusive license, with the right to grant sublicenses for the licensing of E2/T Combi-Gel.E2/T Combi-Gel covers four hormone products for the treatment of hormone deficiencies in men and women.

This modification of the royalties does not apply for the products Estradiol single gel, Testosterone single gel and the combination product Estradiol plus Testosteron” but only and exclusive for E2-NETA Combi Gel.

License Property
Patents
5,891,462 – A Novel Composition for transdermal administration of an Estrogen, a Progestin or a mixture thereof (Combi Gel)
08/058,517 – Administration System for Estradiol (Estradiol Patch)

Products
Gel E2 where estradiol is the sole active ingredient, and where the gel is applied to the skin Gel Testosterone where testosterone is the sole active ingredient and where the gel is applied to the skin
Patch E2 where estradiol is the sole active ingredient and where the patch is applied to the skin
E2-**** Combi Gel where estradiol and *********** are the two active ingredients and where the gel is applied to the skin
Option regarding E2-T Combi gel
E2-T Combi Gel where Estradiol and Testosterone are the two active ingredients and where the gel is applied to the skin

Products shall mean the four pharmaceutical products either dermal gel or patch, for application on the skin, intended for pharmaceutical use with humans for any indication now known or known in the future, and with defined active compounds.

IPSCIO Record ID: 27099

License Grant
The Swiss Company has granted Licensee an exclusive license, with the right to grant sublicenses for the licensing of E2/T Combi-Gel.E2/T Combi-Gel covers four hormone products for the treatment of hormone deficiencies in men and women.
License Property
Patents
5,891,462 – A Novel Composition for transdermal administration of an Estrogen, a Progestin or a mixture thereof (Combi Gel)
08/058,517 – Administration System for Estradiol (Estradiol Patch)

Products
Gel E2 (where Estradiol is the sole active ingredient, and where the gel is applied to the skin) Gel Testosterone (where testosterone is the sole active ingredient and where the gel is applied to the skin)
Patch E2 (where Estradiol is the sole active ingredient and where the patch is applied to the skin)
E2-**** Combi Gel (where Estradiol and *********** are the two active ingredients and where the gel is applied to the skin)
Option regarding E2-T Combi gel
E2-T Combi Gel (where Estradiol and Testosterone are the two active ingredients and where the gel is applied to the skin)

Field of Use
The rights granted apply to the Products which shall mean the four pharmaceutical products either dermal gel or patch, for application on the skin, intended for pharmaceutical use with humans for any indication now known or known in the future, and with defined active compounds.

IPSCIO Record ID: 28841

License Grant
Swiss Licensor hereby grants to the Dutch Licensee the exclusive, sub-licensable right and License to pursue the development in accordance with the Development Plan as required in order to apply for Registration(s) for the Combi-Gel NETA, and upon receipt of such Registration, to manufacture, market, distribute and sell the Product, in the Territory, and to use the Patents and Know-How exclusively for that purpose, all in accordance with the provisions contained in this Agreement and subject to the payment of the Milestone Payments and the Royalty.
License Property
'Combi-Gel NETA' shall mean the Combi-Gel containing Estradiol and Norethindrone acetate in all concentrations as the sole active ingredients for pharmaceutical use with humans developed by Licensor prior to the effective date of this Agreement.

Combi Gel NETA is a transparent, non-staining gel to be applied once-a-day in postmenopausal women.   Based on Licensor's Combi Gel Technology, it delivers transdermal levels of two hormones 17-beta Estradiol and Norethindrone Acetate.  This technology will be used for the development of a hormone replacement therapy gel.

Patent Application Number 08/869,982
Date of Application 05/06/97

IPSCIO Record ID: 6946

License Grant
The Swiss Licensor has granted the Licensee the licensing of XXXX Combi-Gel  with the right to sublicense products.

The Licensor and the Licensee have entered into that certain License and Supply Agreement dated of June 13, 2000, regarding the grant of a License with the right to subLicense products.  This amendment is effective  as defined in the Agreement

License Property
This modification of the royalties only applies and is exclusive for E2-NETA Combi Gel.

IPSCIO Record ID: 203450

License Grant
Licensor grants an exclusive license in the Territory, and, the right to grant sub licenses, to rights under
(a) the Licensor Patents and Technology; and
(b) Licensors rights in any Joint Developments in the Field;
in each case to develop, use, make, have made, sell or otherwise dispose of the Products in the Field; provided, however, that notwithstanding the foregoing, Licensee shall not have the right to make or have made the Products other than as expressly contemplated by or provided in the Manufacturing and Supply Agreement, or to modify in any way the structure or composition of the Products, without the prior written consent of Licensor.
License Property
The patents cover the T-Patch and/or the TE Patch.

Products means the TE Patch and the T-Patch. For the avoidance of doubt, Products does not include Intrinsa.

The Once A Week T Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain testosterone as the single active ingredient at a dosage in vitro of testosterone to be determined, that is intended to be worn for seven consecutive days, which shall be evidenced by either an NDA or a supplement to the NDA for the T Patch or lntrinsa.

The T-Patch means the transdermal patch drug delivery system developed by Licensor that contains testosterone as the single active ingredient at an in vivo dosage bio-equivalent to Intrinsa which is worn for three to four consecutive days, which shall be evidenced by either an NDA, a supplement thereto, or a supplement to the NDA, for Intrinsa, and shall include any minor improvements or modifications to such product that do not require additional development work.

The TE Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain as the active ingredients a combination of testosterone and estrogen at a single dosage in vivo of testosterone to be determined, which dosage shall be in the range of about 50 to about 600 meg/day and which shall he evidenced by an NDA or a supplement thereto.

Field of Use
The Field means transdermal patches that contain testosterone ( or androgen derivatives of testosterone or androgens that convert to testosterone in the body) as the single active ingredient, and transdermal patches that contain the combination of testosterone (or androgen derivatives of testosterone or androgens that convert to testosterone in the body) plus estrogen or other related hormones (e.g. progestin), in each case at dosages of testosterone, androgen derivatives of testosterone or androgens that convert to testosterone in the body (in vivo) in the range of about 50 to about 600 meg/day, for use by women for any indication.

IPSCIO Record ID: 30630

License Grant
The company signed a non-exclusive license agreement  for the 7-day Estradiol patch.
License Property
Estradiol is a hormone replacement therapy for menopausal women.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 145984

License Grant
The Italian Licensee entered into an exclusive license agreement for the Licensors 7-day Estradiol patch for Italy, the Vatican and San Marino (the Territories).
License Property
The 7-day Estradiol patch is a product for the delivery of drug compounds through skin and mucosa.  Estradiol transdermal skin patches are used to treat certain symptoms of menopause.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 30091

License Grant
The company entered into a non-exclusive license agreement for the 7-day Estradiol patch for Chile, and an exclusive license for the Estradiol patch for Bolivia and Ecuador.
License Property
Estradiol is a hormone replacement therapy for menopausal women.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 570

License Grant
The Company shall sell, assign, transfer, convey and deliver to Purchaser, and Purchaser shall purchase, acquire and accept from the Company, all of the Company's right, title and interest in and to those certain assets  (the 'Intellectual Property').
License Property
The Company has developed and owns the certain Intellectual Property which it refers to as the 'U-Strip' Technology.

The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.

Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.

IPSCIO Record ID: 6580

License Grant
The Licensor and Licensee have a license agreement for the Licensor's CPE-215 with Testosterone formulation – Testim.  Testim was was launched in the U.S. in early 2003. The Licensor recently obtained patents that cover the application of testosterone with CPE-215 in the U.S. and in foreign countries that continue through 2023.
License Property
The Licensor's platform drug delivery technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through development of proprietary formulations with molecules such as CPE-215.

Testim® is a gel for testosterone replacement therapy, which is a formulation of our technology with testosterone.

IPSCIO Record ID: 30085

License Grant
The company entered into a non-exclusive license agreement for the 7-day Estradiol patch for Chile.
License Property
Estradiol is a hormone replacement therapy for menopausal women.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 6955

License Grant
The Licensor granted the Licensee an exclusive license to certain patents and patent applications covering certain gel products, including rights to sublicense, in order to develop and market the products in certain territories, including the U.S., Canada, New Zealand, South Africa, Israel, Mexico, China (including Hong Kong) and Indonesia.
License Property
Our products for female sexual health, menopause, contraception and male hypogonadism include our gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen LibiGel, Elestrin, Bio-T-Gel and Pill-Plus, our triple component contraceptive that uses various combinations of estrogens, progestogens and androgens in development for the treatment of FSD in women using oral or transdermal contraceptives.
Field of Use
The rights granted apply to the healthcare for women.

The Licensee is the exclusive licensee in certain territories for issued U.S. patents for these products and additional patent applications have been filed for this licensed technology in the U.S. and several foreign jurisdictions.

IPSCIO Record ID: 356972

License Grant
Licensor grants a worldwide, exclusive, even as to Licensor, license, with the right to grant sublicenses, under the Licensed Technology, to make, have made, use, sell, offer for sale and import and otherwise Commercialize Licensed Products in the Field in the Territory.
License Property
Licensor is a corporation with proprietary transdermal drug delivery technology, and, has completed a Phase 2 Clinical Trial for a patch utilizing a micro-projection system containing a once-daily formulation of parathyroid hormone (PTH) and a Phase 1 Clinical Trial for such a patch containing a once-weekly formulation of PTH.

Licensed Products means the Daily Product and any Product Patch with a New Dosing Duration.

Daily Product means a Product Patch which is intended to deliver PTH formulations to a patient one time each day.

New Dosing Duration shall be any dosing duration, other than once daily, with respect to a Product Patch or Licensed Product. For example, if a Licensed Product has an administration once daily, then a once weekly administration would be a New Dosing Duration.

Pen means the pre-filled cartridge pen device currently marketed by Licensee to administer via injection once daily formulations of the Licensee’s recombinant human PTH analog (1-34) rhPTH (1-34) or manufactured by Licensee to administer a placebo.

Product Patch means a micro-projection array which pierces through the outmost, the stratum corneum, layer of the skin and either in which the micro-projections are coated with a formulation containing PTH as an active pharmaceutical ingredient, to deliver such active pharmaceutical ingredient into or through the skin, in a passive, diffusion-mediated manner, or to form pathways for diffusion-mediated delivery of PTH as an active pharmaceutical ingredient into or through the skin, in each inclusive of an applicator device, API, patch and packaging. For purposes of clarity, the Product Patch shall include all dosage and timed release formulations of PTH.

Field of Use
Field means all uses of PTH.

Licensee currently markets Forteo®, a once-daily formulation of Licensee’s recombinant human PTH analog (1-34) rhPTH(1-34) administered by subcutaneous injection and approved in the United States for the treatment of severe osteoporosis.

FORTEO is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis. FORTEO is used to increase the bone mass in men with primary or hypogonadal osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO is used to treat both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.

IPSCIO Record ID: 256229

License Grant
Licensee desires to acquire certain assets and rights pertaining to Eladur® and obtain a license to Licensor's proprietary TRANSDUR® transdermal delivery technology and other intellectual property to develop and commercialize Eladur®, and Licensor desires to transfer such assets and grant such a license to Licensee.

For the  License to Product, Licensor grants an exclusive license under the Licensed Technology, other than specific third party patents, solely to make, have made, use, import, sell, offer for sale and otherwise develop and Commercialize Products in the Field in the Territory, and, as permitted, an exclusive sublicense under Licensors license to Licensee Patents solely to make, have made, use, import, sell, offer for sale and otherwise Develop and Commercialize Products that contain bupivacaine, and no other Bupivacaine compound as the sole active ingredient, in the Field in the Territory.

Licensor grants to a limited right to use the trademark 'TRANSDUR®' solely in connection with the sale and marketing of Products in the Field within the Territory in accordance with this Agreement.

License Property
Licensor owns and controls rights in and to its product known as Eladur®, which is a transdermal bupivacaine patch based on Licensors proprietary TRANSDUR® transdermal delivery technology.

Bupivacaine shall mean bupivacaine, or any enantiomer, polymorph, salt form, racemate, isomer, diastereomer, tautomer, solvate, hydrate, or ester of bupivacaine.

Product shall mean any transdermal patch containing Bupivacaine as the sole active ingredient, including Eladur® as further described in IND No. 75,436.

TRANSDUR® Technology is defined as pharmaceutical transdermal patch drug delivery systems for use with a range of pharmaceutical preparations for sustained release of medication into the body, wherein the transdermal patch comprises a backing layer; a pressure-sensitive adhesive layer; and a release liner, wherein the pressure-sensitive adhesive layer comprises active agent, polyisobutylene, and plasticizer.

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.
Bupivacaine is an anesthetic (numbing medicine) that blocks nerve impulses in your body. Bupivacaine is used as a local (in only one area) anesthetic. Bupivacaine is given as an epidural injection into the spinal column to produce numbness during labor, surgery, or certain medical procedures.

Field of Use
The agreement is for the rights to develop and commercialize ELADUR®, Licensor's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN).

Postherpetic neuralgia s the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles.  Postherpetic neuralgia is a painful condition that affects your nerves and skin. It is a complication of herpes zoster, commonly called shingles. When the pain caused by shingles doesn't go away after the rash and blisters clear up, the condition is called postherpetic neuralgia.

IPSCIO Record ID: 367578

License Grant
Israeli Licensor hereby grants to the Licensee an exclusive worldwide through multiple tier license, in the Territory, to 1) the Intellectual Property Rights resulting from and/or arising under the Development Plan and/or Development Results including Resulting Patents, and/or the Drug Formulation and/or Product ; and 2) to make, have made, use, have used and/or license the Drug Formulation and/or the Development Results, and 3) to make, have made, sell, have sold, use, have used, license, and/or import Product; and 4) an exclusive license in the Territory to any Patents covering the Drug Formulation and Product to enable the Licensee to make, have made, sell, have sold, and/or use Products. The Licensee shall not use the Drug Formulation and/or the Development Results for any purpose other than exercise of the License. Licensor hereby grants to the Licensee a non-exclusive license, in the Territory under the Licensor Patents, to use the Licensor Formulation Technology to 1) develop, make, have made, and use, the Drug Formulation, and 2) develop, make, have made, sell, have sold, and use, Product.
License Property
Licensor Patents shall mean the patents and/or patent applications covering or disclosing Licensor Formulation Technology; and including but not limited to,  U.S. Patent No. 5,540,934, U.S. Patent No. 5,716,638 and PCT International Application No. PCT/EP95/02397 and any continuations, continuations-in-part, extensions, divisions, substitutions or additions to such applications and all patents which are reissues thereof, re-validations and registrations based thereon, and any and all foreign patents and patent applications corresponding thereto.

5,540,934 – Compositions for applying active substances to or through the skin
5,716,638 – Composition for applying active substances to or through the skin

Product means a pharmaceutical preparation or composition containing the Drug Formulation which is covered by a Valid Patent Claim.

Drug means the Licensees organoselenium drug or materials, as specified in this Agreement, and its racemate, metabolite, derivatives, isomers, polymorphs, crystals.

Drug Formulation means the formulation of the Drug utilizing Licensors Formulation Technology.

Field of Use
Field of use is for Ethosome, a non-invasive, transdermal drug delivery technology.

Ethosomes are phospholipid nanovesicles used for dermal and transdermal delivery of molecules.

IPSCIO Record ID: 28250

License Grant
In May 2015, the Licensee acquired from the Licensor the approved new drug application for the previously-Licensed testerone gel product. Pursuant to the terms of the purchase Agreement, upon commercialization, the Licensee will pay a royalty as a result of commercial sale of the product.
License Property
The Licensor's Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism and hypogonadotropic hypogonadism.
Field of Use
The Licensee acquired a testosterone gel product for commercialization.

IPSCIO Record ID: 282938

License Grant
Licensor shall grant to Licensee a non-exclusive license to make, have made, use, sell and have sold such CombiPatch Product under Confidential Information relating to the CombiPatch Product, including Licensors  Technology, Licensors Patent Rights and any other patents, know-how, improvements, development studies and other information, and any trademarks related to the CombiPatch Product and owned by Licensor, for a royalty of Licensees Net Revenues from sales of the CombiPatch Product so manufactured, in addition to other terms and condition as reasonably agreed between the parties.

Licensor shall supply to Licensee, and Licensee shall purchase from Licensor all of Licensees requirements for the CombiPatch Product for sale in the Territory subject to the terms and conditions set forth herein.  Licensor shall also exclusively supply Licensee, and Licensee shall purchase from Licensor all of Licensees requirements for Licensed Products other than the CombiPatch Product for sale in the Territory.

License Property
The term CombiPatch Product shall mean the transdermal estrogen/progestin patch product which has and is being developed by Licensor solely or jointly with another party and its Affiliates and is marketed under the trademark CombiPatch(TM) in the Territory.

CombiPatch Product, at Licensees option, shall be supplied in finished, packaged and labeled form or in bulk rolls.

The term Licensed Product shall have the meaning set forth in the Licensor License Agreement, as amended. The term Licensed Product or shall mean individually and collectively any Estrogen Transdermal Drug Delivery System or any Combination Estrogen/Progestin Drug Delivery System. A Licensed Product relating to the Estrogen Transdermal Drug Delivery System shall be referred to as an 'Estrogen Product' and a Licensed Product relating to the Combination Estrogen/Progestin Drug Delivery System shall be referred to as a 'Combination Product.'

The term Licensors Technology' shall have the meaning set forth in the Licensor License Agreement in so far as it relates to any combination estrogen/progestin in a polymer adapted for transdermal delivery by application to the epidermis, other than combinations indicated for contraceptive use.

CombiPatch(TM) is a transdermal combination estrogen/progestin delivery system.

Field of Use
This agreement pertains to the drug industry relating to any combination estrogen/progestin in a polymer adapted for transdermal delivery by application to the epidermis, other than combinations indicated for contraceptive use.

CombiPatch (estradiol, norethindrone acetate transdermal system) is a combination of female hormones used to treat the symptoms of menopause such as feelings of warmth in the face, neck and chest, or sudden intense spells of heat and sweating ('hot flashes' or 'hot flushes'); to treat vulvar and vaginal changes.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.